新型偏向性 μ- 阿片受体激动剂奥赛利定的研究进展

晓娜 刘(河北北方学院研究生院，中国;邢台市中心医院麻醉科，邢台市中心医院中心实验室，中国;)
新宇 姚(邢台市中心医院麻醉科，邢台市中心医院中心实验室，中国;)

摘要

奥赛利定作为新型偏向性μ-阿片受体激动剂，在疼痛治疗领域展现出巨大潜力。本文综述了奥赛利定的基本特性、作用机制、药效学特征及临床应用前景。奥赛利定具有独特的化学结构和受体亲和性，通过偏向性激动机制实现强效镇痛的同时降低不良反应风险。在急慢性疼痛管理中，奥赛利定展现出良好的应用前景，特别是对特殊人群的安全性更高。然而，奥赛利定的研发仍面临诸多挑战，包括制剂工艺优化、给药方式创新和长效制剂开发等。此外，本文还探讨了奥赛利定的未来在个体化给药、联合用药和新适应症开发等方面的发展方向。综上所述，奥赛利定有望成为疼痛治疗领域的重要突破，但仍需进一步研究以充分发挥其临床价值。

关键词

奥赛利定；偏向性μ-阿片受体激动剂；镇痛；药代动力学；安全性

参考

吴禧敏, 张晓静, 冯汨, 常惠礼. 治疗成人中重度急性疼痛新药oliceridine. 中国新药杂志. 2023. 32(05): 469-475.

Huang YH, Lee MT, Sieghart W, Knutson DE, Chiou LC. Positive modulation of cerebellar α6GABA A receptors for treating essential tremor: a proof-of-concept study in harmaline-treated mice. 2021 .

Hill DM, DeBoer E. State and Future Science of Opioids and Potential of Biased-ligand Technology in the Management of Acute Pain After Burn Injury. J Burn Care Res. 2023. 44(3): 524-534.

Fossler MJ, Sadler BM, Farrell C, et al. Oliceridine (TRV130), a Novel G Protein-Biased Ligand at the μ-Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. I: Development of a Pharmacokinetic/Pharmacodynamic Model. J Clin Pharmacol. 2018. 58(6): 750-761.

Bachmutsky I, Wei XP, Durand A, Yackle K. ß-arrestin 2 germline knockout does not attenuate opioid respiratory depression. Elife. 2021. 10: e62552.

Urits I, Viswanath O, Orhurhu V, et al. The Utilization of Mu-Opioid Receptor Biased Agonists: Oliceridine, an Opioid Analgesic with Reduced Adverse Effects. Curr Pain Headache Rep. 2019. 23(5): 31.

Muchhala KH, Jacob JC, Dewey WL, Akbarali HI. Role of β-arrestin-2 in short- and long-term opioid tolerance in the dorsal root ganglia. Eur J Pharmacol. 2021. 899: 174007.

DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013. 344(3): 708-17.

Liang DY, Li WW, Nwaneshiudu C, Irvine KA, Clark JD. Pharmacological Characters of Oliceridine, a μ-Opioid Receptor G-Protein-Biased Ligand in Mice. Anesth Analg. 2019. 129(5): 1414-1421.

Nafziger AN, Arscott KA, Cochrane K, Skobieranda F, Burt DA, Fossler MJ. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine. Clin Pharmacol Drug Dev. 2020. 9(5): 639-650.

Cheng JX, Cheng T, Li WH, Liu GX, Zhu WL, Tang Y. Computational insights into the G-protein-biased activation and inactivation mechanisms of the μ opioid receptor. Acta Pharmacol Sin. 2018. 39(1): 154-164.

Altarifi AA, David B, Muchhala KH, Blough BE, Akbarali H, Negus SS. Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. J Psychopharmacol. 2017. 31(6): 730-739.

Liang DY, Li WW, Nwaneshiudu C, Irvine KA, Clark JD. Pharmacological Characters of Oliceridine, a μ-Opioid Receptor G-Protein-Biased Ligand in Mice. Anesth Analg. 2019. 129(5): 1414-1421.

Singla N, Minkowitz HS, Soergel DG, et al. A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty. J Pain Res. 2017. 10: 2413-2424.

Mori T, Takemura Y, Arima T, et al. Further investigation of the rapid-onset and short-duration action of the G protein-biased μ-ligand oliceridine. Biochem Biophys Res Commun. 2021. 534: 988-994.

Soergel DG, Subach RA, Sadler B, et al. First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2014. 54(3): 351-7.

Soergel DG, Subach RA, Burnham N, et al. Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain. 2014. 155(9): 1829-1835.

Viscusi ER, Webster L, Kuss M, et al. A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain. Pain. 2016. 157(1): 264-272.

Viscusi ER, Skobieranda F, Soergel DG, Cook E, Burt DA, Singla N. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J Pain Res. 2019. 12: 927-943.

Beard TL, Michalsky C, Candiotti KA, et al. Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials. Pain Ther. 2021. 10(1): 401-413.

Bergese SD, Brzezinski M, Hammer GB, et al. ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The µ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy. J Pain Res. 2019. 12: 3113-3126.

Bohn LM, Gainetdinov RR, Sotnikova TD, et al. Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci. 2003. 23(32): 10265-73.

Kliewer A, Schmiedel F, Sianati S, et al. Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nat Commun. 2019. 10(1): 367.

Stahl EL, Bohn LM. Low Intrinsic Efficacy Alone Cannot Explain the Improved Side Effect Profiles of New Opioid Agonists. Biochemistry. 2022. 61(18): 1923-1935.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v3i10.33017